Drug facts

Where to inject tirzepatide: stomach, thigh or arm

By David Chen·Editor·Reviewed September 2026

The sites the label names¹

Among its administration instructions, section 2.4 states that the product is injected subcutaneously in the abdomen or thigh, or in the back of the upper arm if another person is administering it. The same section says the injection is given once weekly, at any time of day, with or without meals.

Stomach (abdomen)³

The label names the stomach for injecting yourself. The KwikPen Instructions for Use add one placement detail: inject in the stomach area at least 2 inches from the belly button. The same instructions say you may keep using the stomach week after week, as long as you choose a different spot within it each time.

Thigh²

Yes, you can inject tirzepatide in the thigh. It is the other site the label names for self-injection, and the single-dose vial Instructions for Use put it the same way: you can inject under the skin of your stomach area or thighs. In the label’s own data the thigh gave similar exposure to the stomach, covered below.

Upper arm, if someone else injects¹

The label’s wording is that another person should inject in the back of the upper arm. It does not list the arm as a site for injecting yourself, and the Medication Guide repeats that phrasing. The vial Instructions for Use state the other side of it: someone else can inject in your stomach area, thighs or the back of the upper arms.

Is one site better for results?⁴

No, not for the approved product. The absorption subsection reports a mean absolute bioavailability of 80% following subcutaneous administration, with peak plasma concentration at a median of 24 hours (range 8 to 72 hours), and states that similar exposure was achieved with subcutaneous administration in the abdomen, thigh or upper arm.

So the choice between the three named sites is not a dosing decision, and the label has no “best injection site for weight loss.” The number of milligrams is settled elsewhere, and if the arithmetic between milligrams and the markings on a syringe is what is actually troubling you, that is unpacked in why a vial is dosed in units but prescribed in milligrams.

Red, itchy or a rash at the injection site⁵

A red, itchy or sore patch where you injected is a listed side effect. Injection site reactions appear in the adverse reactions table for Studies 1 and 2 at 6% on 5 mg, 8% on 10 mg and 8% on 15 mg, against 2% on placebo. The footnote to that row explains that the entry pools several related terms: injection site bruising, erythema (redness), pruritus (itching), pain, rash and reaction.

A separate paragraph in the same section reports that these reactions were more frequent in patients who developed anti-tirzepatide antibodies (11.3%) than in those who did not (1%). The wider picture of what was reported, and at what rate against placebo, is in the side effects reported in 5% or more of trial participants.

²Rotation is the one prevention step the instructions give. The vial Instructions for Use say to change the injection site within the area you choose for each dose to reduce the risk of lipodystrophy (pits in the skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps), and not to inject where the skin is tender, bruised, scaly or hard, or into scars.

⁶A local patch is different from an allergic reaction. The Medication Guide says to stop the medicine and get medical help right away for swelling of the face, lips, tongue or throat, problems breathing or swallowing, a severe rash or itching, fainting or dizziness, or a very rapid heartbeat.

What a compounded vial inherits from this¹

A compounded vial arrives with no FDA-approved Instructions for Use, because there are none to arrive with. The site guidance above was written about the approved product, and the practical instructions that govern your own vial come from your prescriber and the pharmacy that made it. Handling it — how it is kept, and for how long — is a separate question, covered in storage and the beyond-use date on a compounded vial. What the injected drug then does is covered in how tirzepatide acts on GIP and GLP-1 receptors.